Abstract library

521 results for "follow-up period".
#1392 How Long Should We Look Up for Recurrence After Resection of Pancreatic Neuroendocrine Tumors?
Introduction: There remains several unsolved issues to be settled about the management of pancreatic neuroendocrine tumors (PNETs) after resection. One of these problems are the follow up period after a complete resection of the tumor.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Asahi Sato
Authors: Sato A, Masui T, Nakano K, Kawaguchi Y, ...
#146 Recurrence characteristics in resected pulmonary typical and atypical carcinoids
Introduction: Pulmonary typical and atypical carcinoids are widely considered indolent, although they can metastasize even with a very long relapse free interval. No standard follow-up strategy exists after a radical resection.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Michela Squadroni
#230 Long-term Follow-up of Tissue Valve Prostheses in Carcinoid Heart Disease
Introduction: Development of carcinoid heart disease (CHD) increases morbidity and mortality. Cardiac valve replacement surgery improves functional class, but tissue prosthesis degeneration can occur early in CHD.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Daniel S Knight
#53 The rise and fall of chromogranin A as an indicator for NET
Introduction: There is now general awareness that treatment with proton pump inhibitors (ppi) may cause moderate rises in circulating concentrations of gastrin and/or chromogranin A (CgA), thus decreasing the specificity of these markers in the diagnosis of neuroendocrine tumors (NETs). Due to their high efficacy, proton pump inhibitors (ppi) are one of the most frequently prescribed classes of drugs worldwide. Several studies in various countries report that 30% or more of in-patients have been prescribed ppi. Patients who are suspected of having a neuroendocrine tumor (NET) often have gastrointestinal (GI) symptoms for which ppi are prescribed and therefore they may be already taking ppi when their first blood sample is assayed for NET markers. We previously encountered a case of extreme rise in CgA which flagged the possibility of a NET, but was later shown to be due to ppi therapy alone. We present CgA and gastrin data in relation to ppi therapy and withdrawal for this patient. In order to see if this was an isolated incident, we audited all laboratory requests for CgA/gastrin in a two-year period and monitored those that provided details of ppi treatment/withdrawal.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Lee Armstrong
Authors: Armstrong L, Ryan K, Ardill J, ...
#1745 High Rate of Second Neoplasms in Patients with a Bronchial Neuroendocrine Tumor
Introduction: Bronchial neuroendocrine tumors (NETs) are classified as typical carcinoids (TC), atypical carcinoids (AC), large cell neuroendocrine carcinomas (LCNEC), or small cell lung carcinomas (SCLC)
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Federica Alessandra Cavalcoli
#1757 Therapeutic Strategies in Patients with Neuroendocrine Neoplasm: 30 Month Follow-Up pf Long Survivors from EPH Mostaganem and EHU Oran Medical Oncology
Introduction: Neuro docrine tumors are poorly known and infrequent tumors are, most of the time, diagnosed late, often occurring between the age of 40 and 60.They mainly appear in the gastro intestinal system, pancreas, bronchi, lungs, thymus and thyroid.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Aicha Bengueddach
#59 Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors
Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Georgios Kanakis
#324 Well-differentiated Pancreatic Neuroendocrine Tumor of Uncertain Behavior: A Case Report
Introduction: A small number of Pancreatic Endocrine Tumors (PET) are well-differentiated tumors(WDET) showing benign or uncertain behavior. Prognosis mainly depends on the presence/absence of liver/bone metastasis.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Joana Couto
#377 Survival and Cause of Death in Patients with Small Bowel Neuroendocrine Tumors
Introduction: Small bowel neuroendocrine tumors (SB NETs) have a reported incidence of approximately 0.5-1 per 100 000 population/yr.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#763 Endoscopic Therapy with Argon Plasma Coagulation for Multiple Type 1 Gastric Carcinoid Tumors
Introduction: Data regarding Type I gastric carcinoids and their evolution in prospective series are scarce, thus treatment and follow-up are not codified.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Rodrigo Castano
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.